The narrative around
Henry Schein (HSIC) is showing a shift as analysts are reassessing its growth and valuation. The stocks experienced a surge due to reasons undisclosed. The
CEO, Stanley Bergman, reportedly sold a significant amount of company shares, while the company's Q4 2025 earnings have been released. The margin stays close to 3%, suggesting stability. A valuation check has been performed, concurrent with a
strategic SWOT insight. HSIC has set new 52-week highs due to better-than-expected earnings and strong Q4 revenue growth across all sectors. HSIC has exceeded Q4 earnings and revenue estimates and has increased its price target to $88.00 at Mizuho, $61 at Morgan Stanley, and $92 at JPMorgan.
Wells Fargo has been positive about HSIC's stock price. Interestingly,
Artisan Partners Limited Partnership has purchased more HSIC shares. Several analysts remain conflicted about HSIC alongside other healthcare names like Delcath Systems and Certara. There was a notable stagnancy in organic growth following the CEO transition. However, the Q4 EPS topped by 4c and guidance was offered.
Henry Schein HSIC News Analytics from Tue, 05 Aug 2025 07:00:00 GMT to Sat, 28 Feb 2026 17:02:56 GMT -
Rating 8
- Innovation 3
- Information 6
- Rumor -2
